1stOncology™: Cancer Intelligence Service – Page 14456 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Sumitomo Dainippon Pharma Announces First-ever Inclusion in Dow Jones Sustainability Indices (DJSI)

On September 21, 2017 Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) reported that it has been included in the Dow Jones Sustainability Asia/Pacific Index (DJSI Asia/Pacific), the Asia Pacific subset of the 2017 Dow Jones Sustainability Indices (DJSI), a representative benchmark for socially responsible investing (SRI)* (Press release, Dainippon Sumitomo Pharma, SEP 21, 2017, View Source [SID1234520583]). This is a first for the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The DJSI are SRI indices developed through collaboration between S&P Dow Jones Indices(U.S.) and RobecoSAM(Switzerland). Sustainability of corporate activity is evaluated on the basis of three dimensions —economic, environmental, and social— with recognition given to outstanding companies.

Sumitomo Dainippon Pharma’s selection for inclusion in the 2017 DJSI was based on its high evaluation results with respect to criteria including Product Quality and Recall Management, Innovation Management, and Health Outcome Contribution. The Company is already a component of global SRI indices FTSE4Good Index Series (for 15 consecutive years), and Morgan Stanley Capital International (MSCI) Global Sustainability Indexes (for six consecutive years). Moreover, starting from the current fiscal year, the Company is included in Morningstar Socially Responsible Investment Index(MS-SRI), an SRI index of Japanese listed companies.

Our responsibility to society, encapsulated in our Corporate Mission, is "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," and we define the implementation of this mission as our "CSR management." We remain committed to the practice of CSR management and the sustainable enhancement of corporate value.

*: Socially Responsible Investment (SRI)
Investment strategy whereby potential investors take into account assessments of a company’s policies and actions in respect of environmental issues, corporate social responsibility and governance, in addition to analysis of financial performance.

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

On September 21, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, reported that the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26 at 2:30 p.m. EDT, in Track 2-Odeon at the Sofitel Hotel, New York. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs (Press release, Cyclacel, SEP 21, 2017, View Source [SID1234520582]).

A live webcast of the presentation will be available through the Company’s corporate website: www.cyclacel.com. The webcast will be archived for 90 days.

Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference

On September 21, 2017 –(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York. Thomas Lynch, chief scientific officer, will answer questions about the company at 11:00 a.m. EDT (Press release, Bristol-Myers Squibb, SEP 21, 2017, View Source [SID1234520581]).

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.

BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum

On September 21, 2017– BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, reported that Co-Chief Executive Officer Adi Mohanty will participate in a panel discussion at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston (Press release, BioTime, SEP 21, 2017, View Source [SID1234520580]).

The panel, titled "Financing Innovation: Attracting Investment" is at 2:00pm ET/11:00am PT. The discussion will be moderated by Rich Daly, Chairman and CEO of Neuralstem. Panelists include Mark Barrett, Entrepreneur-in-Residence, Frazier Healthcare Partners, David Grainger, Ph.D., CEO of Methuselah Health and Partner at Medicxi, and Nora Yang, Director, Portfolio Management & Strategic Operations at the National Center for Advancing Translational Sciences, National Institutes of Health.

Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing, and delivery challenges. Healthcare investors and leading researchers also participate.

EAGLE PHARMACEUTICALS LICENSES JAPANESE RIGHTS FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE AND RAPID INFUSION INJECTION PRODUCTS TO SYMBIO PHARMACEUTICALS LIMITED

On September 20, 2017 Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") and SymBio Pharmaceuticals Limited ("SymBio") (Tokyo Stock Exchange/JASDAQ 4582) reported that the Company has licensed to SymBio rights under Eagle’s intellectual property to develop, market and sell Eagle’s bendamustine hydrochloride ("bendamustine HCl") ready-to-dilute ("RTD") and rapid infusion ("RI") injection products in Japan (Press release, Eagle Pharmaceuticals, SEP 20, 2017, View Source [SID1234540126]).

SymBio will be responsible for securing regulatory approval of the RTD and RI injection products using the licensed technology in Japan with a target for approval of a product in 2020. SymBio currently markets TREAKISYM in Japan, a lyophilized powder formulation of bendamustine HCl indicated for chronic lymphocytic leukemia ("CLL"); relapsed or refractory low-grade Hodgkin’s lymphoma ("NHL"); mantle cell lymphoma ("MCL"); and as a first line treatment of low-grade NHL and MCL. According to SymBio, 12-month sales ended June 30, 2017 in Japan for TREAKISYM were $52 million, due to the approval of first line treatment for NHL and MCL in December 2016. SymBio has estimated that sales of TREAKISYM are estimated to grow to $90 million in 2018.

A 50 ml RI or rapid infusion presentation of bendamustine hydrochloride injection is currently marketed in the U.S. by Teva Pharmaceutical Industries, Ltd. ("Teva") as BENDEKA (bendamustine HCl) Injection. BENDEKA currently has a 97% market share of the bendamustine market, and Teva has forecasted the North American market for bendamustine to be approximately $600 – $660 million in sales in 2017. BENDEKA’s low volume infusion and short infusion time represents an important benefit to both patients and healthcare providers.

Pursuant to the terms of the license with SymBio, Eagle will receive a $12.5 million upfront milestone payment, and may be entitled to additional milestone payments upon approval and the achievement of cumulative sales thresholds. The Company will also receive royalties on future net sales of the licensed bendamustine products.

"This is an important example of the value of the Eagle portfolio to patients worldwide and a first step in expanding outside the U.S. for our differentiated products. We look forward to SymBio’s future approval and successful commercialization of bendamustine HCI in Japan," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated, "In-licensing Eagle’s ready-to-dilute and rapid infusion injection products will enable SymBio to extend the product life and continue to maximize the value of TREAKISYM over the product life while bringing significant benefits to patients and healthcare providers in Japan."